International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 11954 - 11954
Published: Nov. 7, 2024
Lung cancer is the leading cause of cancer-related mortality worldwide, primarily driven by genetic mutations. The most common alterations implicated in lung include mutations
Language: Английский
Han-guk hyeonmigyeong hakoeji/Applied microscopy, Journal Year: 2025, Volume and Issue: 55(1)
Published: Jan. 20, 2025
Abstract The development of bispecific antibodies (BsAbs) represents a significant advancement in therapeutic antibody design, enabling the simultaneous targeting two different antigens. This dual-targeting capability enhances efficacy, particularly complex diseases like cancer, where tumor heterogeneity presents challenge for traditional treatments. By bridging distinct pathways, BsAbs can improve specificity and minimize off-target effects, making them invaluable contexts. Integrating advanced imaging techniques, Correlative Light Electron Microscopy (CLEM), offers unique opportunity to visualize dynamic interactions within cellular environments. CLEM combines strengths optical electron microscopy, allowing researchers observe real-time antibody-antigen at nanoscale resolution. synergy not only deepens our understanding BsAbs’ mechanisms action but also provides critical insights into their spatial distribution, binding kinetics, functional dynamics live cells. In this review, integration paves way targeted strategies, fostering more effective treatments that adapt complexities disease pathology.
Language: Английский
Citations
0
Therapeutic Advances in Medical Oncology, Journal Year: 2025, Volume and Issue: 17
Published: Jan. 1, 2025
Lung cancer is the leading cause of all cancer-related deaths in United States and remains a global health challenge. While targeted therapy has revolutionized treatment landscape nonsmall cell lung cancer, many patients lack actionable mutations. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), have significantly impacted outcomes last decade. Some patients, however, never respond or become refractory to ICIs. Newer therapies aimed at augmenting system enhancing antitumor effects are currently being explored. Adoptive (ACT) employs T cells isolated from either tumors peripheral blood often engineers them effect response. Chimeric antigen receptor (CAR-T) therapy, engineered tumor-infiltrating lymphocytes examples adoptive cellular therapies. CAR-T been successful hematological malignancies with several CAR products gaining approval cancers. The success ACTs cancers fueled research into role these solid including cancer. Many trials had early promising results, clinical enrolling. There limitations efficacy ACTs, as well risks benefits individual subtypes ACT. With growing knowledge about tumor antigens more advanced engineering, there potential for ACT result durable responses immunologically “cold” tumors. Here, we review major evidence supporting their use challenges, future perspectives ACTs. Additionally, include engagers mRNA vaccine studies combinatorial strategies
Language: Английский
Citations
0
Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 255 - 255
Published: Feb. 28, 2025
Background/Objectives: COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic since its outbreak in 2019. As an increasing number of variants have emerged, especially concerning such Omicron BA.1, BA.2, XBB.1, EG.5, which can escape the immune system and cause repeated infections, they exerted significant pressure on monoclonal antibodies treatment approaches for COVID-19. Broad spectrum antiviral medication was urgently needed. In this study, we developed several bispecific based IgG-scFv format one trispecific antibody containing Fab fragments with different anti-virus mechanisms studied previously. The are from h11B11, S2P6, S309 respectively. Method: all recombinant were expressed HEK 293. pseudoviruses’ neutralization assay virus challenge to BALB/c mice deployed assess efficiency vitro vivo. Results: exhibited favorable pseudoviruses activity, IC50 values ranging 8 591 ng/mL. performed even better, 5 27 Furthermore, confirmed that antibodies, including antibody, had decent therapeutic efficacy. Conclusions: our study provided supplements measures COVID-19 multispecific supporting great potential strategy dealing emerging pathogens.
Language: Английский
Citations
0
Surgical Oncology Insight, Journal Year: 2025, Volume and Issue: unknown, P. 100128 - 100128
Published: March 1, 2025
Language: Английский
Citations
0
Advances in experimental medicine and biology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Current Treatment Options in Oncology, Journal Year: 2024, Volume and Issue: 25(11), P. 1337 - 1344
Published: Oct. 11, 2024
Language: Английский
Citations
3
Cancers, Journal Year: 2024, Volume and Issue: 16(22), P. 3780 - 3780
Published: Nov. 9, 2024
Lung cancer, both non-small cell and small cell, harbors a high propensity for spreading to the central nervous system. Radiation therapy remains backbone of management brain metastases. Recent advances in stereotactic radiosurgery have expanded its indications ongoing studies seek elucidate optimal fractionation coordination with systemic therapies, especially targeted inhibitors intracranial efficacy. Efforts whole-brain radiotherapy aim preserve neurocognition investigate need prophylactic cranial irradiation. As novel combinatorial strategies are tested prognostic/predictive biomarkers identified tested, metastases lung cancer will become increasingly personalized optimally balance efficacy preserving neurocognitive function patient values.
Language: Английский
Citations
2
Medical Oncology, Journal Year: 2023, Volume and Issue: 41(1)
Published: Dec. 27, 2023
Language: Английский
Citations
4
ChemBioChem, Journal Year: 2024, Volume and Issue: 25(17)
Published: June 25, 2024
Molecular engineering enables the creation of aptamers with novel functions, but prerequisite is a deep understanding their structure and recognition mechanism. The cellular-mesenchymal epithelial transition factor (c-MET) garnering significant attention due to critical role c-MET/HGF signaling pathway in tumor development invasion. This study reports strategy for constructing chimeric that bind both c-MET other specific proteins. was identified be molecular target DNA aptamer, HF3-58, selected through cell-SELEX. binding mechanism HF3-58 were systematically studied, revealing scaffold, recognition, redundancy regions. Through design, region replaced possessing stem-loop structures, yielding bispecificity A bispecific aptamer HF-3b showed ability mediate adhesion T-cells cells, suggesting prospective utility immunotherapy. These findings suggest can serve as platform diverse multifunctional ligands targeting c-MET. Moreover, comprehensive mechanisms will provide guidance design functional aptamers, significantly expanding potential applications.
Language: Английский
Citations
1
Springer briefs in molecular science, Journal Year: 2024, Volume and Issue: unknown, P. 35 - 56
Published: Jan. 1, 2024
Language: Английский
Citations
0